Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009300 | 0.88 | DRD3 (0.42) | MTNR1AMTNR1BDRD3DRD2KDR | |
| SCHEMBL16082810 | 0.85 | MTNR1A (0.51) | MTNR1AMTNR1BDRD3DRD2ENPP2 | |
| SCHEMBL13213520 | 0.84 | EPHX2 (0.44) | DRD3DRD2KDRPDGFRB | |
| SCHEMBL3534053 | 0.80 | HPGD (0.43) | MTNR1AMTNR1BDRD3DRD2KDR | |
| SCHEMBL3534365 | 0.80 | NPC1 (0.49) | DRD3DRD2KDRPDGFRB | |
| SCHEMBL3530723 | 0.79 | KDR (0.47) | DRD3DRD2KDRPDGFRB | |
| SCHEMBL3530658 | 0.78 | MTNR1A (0.39) | MTNR1AMTNR1BDRD3DRD2KDR | |
| SCHEMBL16082811 | 0.78 | MTNR1A (0.52) | MTNR1AMTNR1BDRD3DRD2CA12 | |
| SCHEMBL3530715 | 0.78 | DRD2 (0.44) | DRD3DRD2KDRPDGFRB | |
| SCHEMBL3530610 | 0.78 | EPHX2 (0.52) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | MTNR1A 3083/4885MTNR1B 1140/4885DRD3 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.